Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Jun
08
Today In Oncology
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
Overall Survival With EBRT in Hepatocellular Carcinoma
SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo